Nafarelin
Title: Nafarelin
CAS Registry Number: 76932-56-4
CAS Name: 6-[3-(2-Naphthalenyl)-D-alanine]luteinizing hormone-releasing factor(pig)
Additional Names: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolylglycinamide; [6-[3-(2-naphthyl)-D-alanine]] LHRH; D-nal(2)6-LHRH; NAG
Molecular Formula: C66H83N17O13
Molecular Weight: 1322.47
Percent Composition: C 59.94%, H 6.33%, N 18.01%, O 15.73%
Literature References: Synthetic peptide agonist analog of LH-RH, q.v. Prepn: J. J. Nestor et al., US 4234571 (1980 to Syntex); eidem, J. Med. Chem. 25, 795 (1982). Suppression of luteal and placental function in baboons: B. H. Vickery et al., Fertil. Steril. 36, 664 (1981). Inhibition of ovulation in humans: J. A. Gudmundsson et al., Contraception 30, 107 (1984). Radioimmunoassay in plasma and serum: C. Nerenberg et al., Anal. Biochem. 141, 10 (1984). Kinetics and tissue disposition in animals: N. I. Chu et al., Drug Metab. Dispos. 13, 560 (1985). Clinical evaluation in benign prostatic hyperplasia: C. A. Peters, P. C. Walsh, N. Engl. J. Med. 317, 599 (1987); in endometriosis: M. R. Henzl et al., ibid. 318, 485 (1988). Review of clinical studies: P. G. Hoffman et al., J. Androl. 8, Suppl., S17-S22 (1987).
 
Derivative Type: Monoacetate
Molecular Formula: C66H83N17O13.C2H4O2
Molecular Weight: 1382.52
Percent Composition: C 59.08%, H 6.34%, N 17.22%, O 17.36%
Properties: mp 188-190°. [a]D25 -27.4° (c = 0.9 in acetic acid).
Melting point: mp 188-190°
Optical Rotation: [a]D25 -27.4° (c = 0.9 in acetic acid)
 
Derivative Type: Acetate hydrate
CAS Registry Number: 86220-42-0
Manufacturers' Codes: RS-94991-298
Trademarks: Nacenyl (Syntex); Nasanyl (Yamanouchi); Synarel (Syntex); Synrelina (Syntex)
Line Formula: C66H83N17O13.xC2H4O2.yH2O
 
Therap-Cat: Treatment of endometriosis.
Keywords: LH-RH Agonist.

Others monographs:
ClofentezinePrazosinErgocorninePotassium Nitrate
Vitamin ABiotinLithium HydroxideNiaprazine
FriedelinDipyridamoleIsopyrocalciferolFormic Acid
MirtazapineNeomycinDPQAchillea
©2016 DrugLead US FDA&EMEA